Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Thailand Inflation Remains Negative for 10th Straight Month in January 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Cresco Labs Inc. and Columbia Care are cannabis and medical marijuana companies that have previously announced their merger through an acquisition deal. In March 2022, they agreed to a transaction that would have created the largest cannabis operator in the United States, but the agreement seems to have gone up in smoke.
Cresco Labs and Columbia made a new announcement on Monday, July 31, stating they have terminated their $2 billion merger deal. This development comes as the industry is waiting for banking reforms, as per CNBC.
Moreover, it was suggested that the contract has been called off as the cannabis industry has been showing indications of a slowdown as it also deals with various economic issues and challenges with regulators. The cannabis companies mutually agreed to scrap their agreement, so there will be no penalties or fees to pay for both parties.
Another reason for the failure of the merger is the fact that Cresco Labs and Columbia Care were not able to unload enough assets required to secure the regulators' seal of approval. They were given the June 30 deadline for this but failed to comply.
"In light of the evolving landscape in the cannabis industry, we believe the decision to terminate the planned transaction is in the long-term interest of Cresco Labs and our shareholders," Cresco Labs' co-founder and chief executive officer, Charles Bachtell, said in a press release.
"We want to express our sincere gratitude to Columbia Care for their valuable collaboration and dedication during this transaction. While this is not the outcome we originally hoped for, we are confident Cresco Labs is in a stronger position moving forward."
Columbia Care's co-founder and CEO, Nicholas Vita, added, "After careful consideration, we are confident in the mutual decision to move forward as separate, standalone companies. This is the best path forward for Columbia Care's employees, customers, and shareholders. We are thankful for the collaboration and partnership with the Cresco team throughout this extensive process."
Photo by: Kimzy Nanney/Unsplash
